

**AMENDMENTS TO THE CLAIMS**

The claims as listed below will replace all prior listings and presentations of claims in the above-identified application.

Please amend Claim 2 and 17, cancel Claims 21-36, and add new Claims 37-41 as follows:

1. (Canceled).
2. (Currently Amended) An implant for treating an ocular disorder ~~glaucoma in an eye~~, said implant having a longitudinal implant axis and comprising:

an outflow portion through which said longitudinal implant axis passes, said outflow portion shaped and sized to be:

(a) introduced into Schlemm's canal of ~~[[the]]~~ an eye with said portion of said longitudinal implant axis at an angle to Schlemm's canal; and

(b) received at least partially within Schlemm's canal regardless of a rotational orientation of the outflow portion about said longitudinal implant axis during said introduction;

a plurality of longitudinally spaced openings in the outflow portion, the openings allowing fluid to communicate from a lumen within the outflow portion to a location outside the outflow portion;

an inflow portion configured to be positioned within ~~[[the]]~~ an anterior chamber ~~of the eye~~ so as to permit communication of fluid from the anterior chamber ~~of the eye~~ to the outflow portion; and

an anchoring member extending from the implant and being disposed distally of the longitudinally spaced openings;

wherein said longitudinal implant axis extends through ~~[[the]]~~ a trabecular meshwork of the eye and is generally orthogonal to Schlemm's canal during said fluid communication.

3. (Canceled).
4. (Canceled).
5. (Canceled).
6. (Canceled).

7. (Canceled).
8. (Canceled).
9. (Canceled).
10. (Canceled).
11. (Canceled).
12. (Canceled).
13. (Previously presented) The implant of Claim 2, wherein the outflow portion has a distal end with a transverse dimension that varies along the longitudinal implant axis.
14. (Previously presented) The implant of Claim 13, wherein the distal end of the outflow portion has a generally conical shape.
15. (Previously presented) The implant of Claim 13, wherein the distal end of the outflow portion has at least one sloped surface.
16. (Previously presented) The implant of Claim 2, wherein the anchoring member comprises a surface that is generally transverse to the longitudinal implant axis.
17. (Currently amended) The implant of Claim 13 [[2]], wherein the distal end and the outflow portion are integrally formed.
18. (Previously presented) The implant of Claim 2, further comprising an intermediate section between the inflow portion and the outflow portion.
19. (Previously presented) The implant of Claim 2, wherein at least a portion of the implant is configured to reside within the trabecular meshwork of the eye.
20. (Previously presented) The implant of Claim 2, wherein the outflow portion is shaped and sized to be introduced through Schlemm's canal of the eye.
- 21.-36. (Canceled).
37. (New) The implant of Claim 2, wherein the implant comprises a therapeutic drug.
38. (New) The implant of Claim 37, wherein the implant comprises a polymer.
39. (New) The implant of Claim 37, wherein the implant includes a first portion and a second portion that is appended from the first portion, and wherein the first portion includes the lumen and the second portion carries the therapeutic drug.
40. (New) The implant of Claim 37, wherein at least a portion of the implant is coated with the therapeutic drug.

**Application No.:** 10/667,580  
**Filing Date:** September 22, 2003

41. (New) The implant of Claim 37, wherein the implant comprises a biocompatible material with the therapeutic drug coated thereon.